Health
First comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC – News-Medical.Net
Oncotarget Volume 11, Issue 34 features Figure 1, “BRAF inhibitor-induced changes in cell viability,” by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprisin…
Oncotarget Volume 11, Issue 34 features Figure 1, “BRAF inhibitor-induced changes in cell viability,” by Pickles, et al. which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
Resistance to BRAF inhibition in CRC arises in part through the generation and activation of RAF dimers resulting in MEK-ERK pathway reactivation.
The Oncota…
-
General15 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
Business14 hours agoWhy Antipa, Cettire, Magnetic Resources, and Steadfast shares are pushing higher
-
General16 hours agoToo skewed, too gentlemanly | The Spectator Australia
-
General17 hours agoAlbanese beats drum on economy as trade clouds gather